stockportfolio.pro
Ocular Therapeutix, Inc. (OCUL)
Healthcare · Biotechnology · NasdaqGM
Ocular Therapeutix, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.89M | $1.92M | $1.99M | $4.23M | $17.40M | $43.52M | $51.49M | $58.44M | $63.72M | $51.95M |
| Gross profit | $1.44M | $1.47M | $1.52M | $1.90M | $15.32M | $39.12M | $46.95M | $53.16M | $58.10M | $45.38M |
| Net income | $-44.70M | $-63.39M | $-59.98M | $-86.37M | $-155.64M | $-6.55M | $-71.04M | $-80.74M | $-193.51M | $-265.94M |
| Net margin | -2369.0% | -3296.2% | -3014.0% | -2043.3% | -894.3% | -15.1% | -138.0% | -138.1% | -303.7% | -511.9% |
Source: Ocular Therapeutix, Inc. SEC filings (10-K). 14 years of history available in the interactive view.
Explore 14 years of Ocular Therapeutix, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track OCUL in your portfolio →
Ocular Therapeutix, Inc. financial history by metric
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Ocular Therapeutix, Inc. — frequently asked questions
What is Ocular Therapeutix, Inc.'s revenue?
Ocular Therapeutix, Inc. (OCUL) reported revenue of $51.95M for fiscal year 2025, down 18.5% from the prior year, according to its SEC filings.
Is Ocular Therapeutix, Inc. profitable?
No — OCUL reported a net loss of $-265.94M in fiscal 2025.
What is OCUL's P/E ratio?
Ocular Therapeutix, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Ocular Therapeutix, Inc. growing?
OCUL's revenue grew at roughly 24.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Ocular Therapeutix, Inc. have?
As of fiscal year 2025, OCUL carried roughly $71.34M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Ocular Therapeutix, Inc.'s gross margin?
OCUL's gross margin was 87.3% in fiscal 2025 — gross profit of $45.38M on revenue of $51.95M.
What is Ocular Therapeutix, Inc.'s market cap?
Ocular Therapeutix, Inc. (OCUL) has a market capitalization of about $1.92B, based on the latest data in our nightly-refreshed cache.
When does Ocular Therapeutix, Inc.'s fiscal year end?
OCUL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Ocular Therapeutix, Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.